非小细胞肺癌组织P^(53)基因突变的研究  

Detection of P^(53) gene mutation in non-small cell lung cancer by PCR-SSCP analysis

作　　者：关赛芳[1] 许凯黎[1] 廖美琳[2] 丁嘉安 陈复华[1] 

机构地区：[1]上海市肿瘤研究所,200032 [2]上海市胸科医院 [3]上海市第1肺科医院

出　　处：《肿瘤防治研究》1997年第3期131-134,共4页Cancer Research on Prevention and Treatment

基　　金：上海市科委课题

摘　　要：本文旨在研究非小细胞肺癌患者发生抑癌基因P53基因的突变量的状况，经采用PCR-SSCP法分析63例非小细胞肺癌和5例正常胎儿肺组织在外显予5、6、7和8中发生的点突变，NSCLC总突变率为49．2％（31／63）。5例正常胎肺组织未出现P53基因突变，63例NSCLC患者中，37例磷癌，16例为腺癌和10例鳞除混合癌，其突变率分别为48．6％，50％和50．0％，与肿瘤组织类型无关。Ⅰ期19例，Ⅱ期22例和Ⅲ例22例，其突变率分别为47.5％，45．4％和54．5％，Ⅲ期突变率稍高，但无统计学意义。本结果证明肺癌组织存在P53基因点突变可能为肺癌发生的关键基因之一。The present report was to investigate into P53 gene mutation in patients with NSCLC. Point mutation in exon 5, 6, 7 and 8 were examined by polymerase chain and d embryonic tissue of the lung. Somatic P53 mutations were detected in 31 of 63 tumors (49. 2% ), According to TNM Stages, there was no difference between P53 gene alteration and NSCLC staging, such as 47. 5% (9/19) for stage I, 45. 5%(10/22) for stage Ⅱ and 54. 4% (12/22) for stage Ⅲ No P53 mutation was found in 5 examined embryonic tissues of the lung. P53 mutations were detected in 37 squamous carcinoma (48. 6% ), 16 adenocarcinoma (50% ) and 10 squamous-adenoid carcioma (50. 0% ) of NSCLC tumors. There was no significant difference between the mutation frequencies and the histological types as well as staging.These results showed that alterlation of P53 suppressor gene through a point mutation have occured in various stages of NSCLC. It was suggested that P53 gene mutaions may play a very important role in human brochial carcinogensis.

关 键 词：非小细胞性 肺癌 P53基因 点突变 外显子 肺肿瘤 

分 类 号：R734.202[医药卫生—肿瘤] R730.231.3[医药卫生—临床医学]